• I-BET-762: BET Inhibitor Workflows for Inflammation & Cancer

  2026-05-27

  I-BET-762, a potent BET inhibitor, enables precise modulation of epigenetic and inflammatory pathways in both cancer and preclinical inflammation models. Recent studies reveal its ability to synergize with ferroptosis inducers and optimize transcriptional programs, offering researchers a robust, evidence-backed reagent for advanced experimental designs.

• A20 Modulates Oxidized Self-DNA Inflammation in Acute Kidney

  2026-05-27

  A recent study elucidates how the ubiquitin-editing enzyme A20 attenuates inflammation in acute kidney injury (AKI) triggered by oxidized self-DNA, primarily by inhibiting the NLRP3 inflammasome. These findings reveal a mechanistic pathway that could inform future anti-inflammatory strategies for sterile kidney injury and related inflammatory pathologies.

• Azilsartan Medoxomil Outperforms Antihypertensives: Meta-Ana

  2026-05-26

  A new systematic review and network meta-analysis demonstrates that azilsartan medoxomil (TAK 491) at 80 mg achieves the highest efficacy in lowering both systolic and diastolic blood pressure among first-line antihypertensive agents for mild-to-moderate hypertension. These findings refine our understanding of optimal ARB selection and support further translational research in blood pressure regulation.

• Red Blood Cell Lysis Buffer: Mechanism, Benchmarks & Workflo

  2026-05-26

  Red Blood Cell Lysis Buffer (K1169) delivers selective erythrocyte removal by ammonium chloride-mediated lysis, preserving nucleated cell integrity. This dossier details its biological rationale, validated workflows, and performance boundaries, establishing it as a reproducible standard for blood sample preparation in flow cytometry and molecular assays.

• THZ1: Transforming Cancer Research via Covalent CDK7 Inhibit

  2026-05-25

  Explore how THZ1, a potent covalent CDK7 inhibitor, is redefining cancer research through unique transcriptional regulation and innovative selectivity. This article offers advanced protocol guidance and bridges recent super-enhancer biology with practical laboratory applications.

• Dabigatran in Anticoagulation Research: Mechanisms, Innovati

  2026-05-25

  Explore Dabigatran's unique role in anticoagulation research, from its precise thrombin inhibition mechanism to advanced applications and assay optimization. This guide offers a scientific perspective that goes beyond protocols, highlighting new insights for researchers.

• Innovative In Vitro Metrics for Drug Response Assessment in

  2026-05-24

  Schwartz's dissertation introduces a critical evaluation of how anti-cancer drug effects are measured in vitro, distinguishing between relative and fractional viability as separate yet complementary readouts. This work clarifies methodological nuances, enabling researchers to better interpret proliferation and cell death outcomes, and supports optimization of preclinical drug evaluation strategies.

• Bufalin: Cardiotonics Empowering Triple-Negative Breast Canc

  2026-05-23

  Bufalin, a cardiotonic steroid, is redefining oncology workflows by enabling targeted STK33 degradation and apoptosis induction in triple-negative breast cancer (TNBC) cells. This article translates cutting-edge findings into actionable protocols, troubleshooting guidance, and advanced applications for researchers deploying APExBIO's high-purity Bufalin in translational cancer research.

• Neuromedin S (rat): Technical Guidance for GPCR Assays

  2026-05-22

  Neuromedin S (rat) provides a defined peptide agonist for activating neuromedin U receptor signaling in rat-based GPCR/G protein research. It is suited for studies of energy homeostasis regulation and stress response but is not intended for diagnostic or medical use. Proper solubility, handling, and storage protocols are essential to maintain experimental integrity.

• Nanoparticle-Mediated PTEN mRNA Delivery Reverses Trastuzuma

  2026-05-22

  This paper introduces a pH-responsive nanoparticle system for systemic delivery of PTEN mRNA to overcome trastuzumab resistance in HER2-positive breast cancer. By restoring PTEN function and inhibiting the PI3K/Akt pathway, the study demonstrates a promising strategy for enhancing monoclonal antibody therapy efficacy.

• Azathramycin A: Macrolide Antibiotic for Tuberculosis Models

  2026-05-21

  Azathramycin A, a macrolide antibiotic, offers precise inhibition of Mycobacterium tuberculosis ribosomes, making it a gold-standard tool for dissecting protein synthesis and resistance mechanisms in tuberculosis research. Its reproducibility and specificity streamline in vitro infection models while supporting advanced resistance profiling.

• MOG (35-55) Peptide: Optimizing Autoimmune Encephalomyelitis

  2026-05-21

  MOG (35-55) Peptide enables highly reproducible modeling of experimental autoimmune encephalomyelitis (EAE), the gold standard for multiple sclerosis research. This guide delivers stepwise protocol enhancements, troubleshooting strategies, and translational insights from cutting-edge interferon signaling studies, ensuring reliable data for neuroinflammation and autoimmune disease research.

• Rapamycin (Sirolimus): mTOR Inhibition, Autophagy, and Neuro

  2026-05-20

  Explore how Rapamycin (Sirolimus) advances mTOR pathway research, with a focus on autophagy, neuroinflammation, and neuropathic pain models. This in-depth analysis uniquely bridges molecular mechanisms with translational assay decisions.

• FLOT1-FOSL2-EphA2 Axis Regulates Microglial Polarization in

  2026-05-20

  This study uncovers the mechanistic role of the FLOT1-FOSL2 interaction in promoting EphA2 transcription and activating the p38/MAPK pathway, which drives neurotoxic microglial polarization in Alzheimer's disease. By targeting this signaling axis, researchers demonstrate improved cognitive outcomes and reduced neuroinflammation, highlighting a promising therapeutic pathway for modulating microglial responses in neurodegenerative disease models.

• HBsAg Hijacks TBK1 to Suppress Interferon and Trigger Autoph

  2026-05-19

  This study uncovers how hepatitis B surface antigen (HBsAg) directly manipulates TANK-binding kinase 1 (TBK1) to suppress type I interferon signaling and induce early autophagy, illuminating a sophisticated HBV immune evasion strategy. The findings clarify molecular cross-talk between innate immunity and autophagic processes in chronic hepatitis B and pinpoint new mechanistic targets for antiviral research.

406 records 7/28 page Previous Next First page 上5页 678910 下5页 Last page